Skip to main content
Equibles
BMRN logo

BMRN · Biomarin Pharmaceutical Inc

Track BMRN — free

Use BMRN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BMRN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$69.33 +2.34 (+3.49%) At close · Aug 19
Market Cap
$12.97B
Shares
193.57M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$69.33 Open$68.17 Day$67.75–69.62 52W close$49.67–70.24 Avg vol 30d2.0M Short int12.5M · 6.5% float · 7.4d Short vol52% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 14.9 · calm Equity put/call 0.64
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +21%
      above
      Price vs 50-day avg +15%
      above
      RSI (14) 69
      neutral
      MACD trend Positive
      52-week position 96%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +19%
      trailing
      6-month return +13%
      trailing
      YTD return +17%
      this year
      Relative strength +3%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $60 › 200d $57 — 50d above 200d
      Institutional flow Accumulating
      +1% holders QoQ · +88 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      6.46% of float · ▼ -12.7% MoM · 7.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      564 holders — mid 3-yr range
      Squeeze score 65
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +18%
      Y/Y
      EPS growth −19%
      Y/Y
      Free cash flow $725.0M
      Valuation P/E 171.8
      rich
      Balance sheet $714.5M
      net cash
      Quant / Vol
      risk profile
      Moderate
      Volatility 35%
      annualized · 1-yr
      Max drawdown −22%
      past year
      ATR 2.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed May 4, 2026
      Total Revenues · full-year 2026 $3.83B – $3.93B
      Prior guidance period ended · from the 8-K filed Oct 27, 2025
      Non-GAAP Diluted EPS · full-year 2025 $3.50 – $3.60
      Guided vs delivered · last 1 settled
      Total revenues 2024
      guided up to $3B
      $2.85B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +21% Bullish
      Price vs 50-day avg
      +15% Bullish
      RSI (14)
      69 Neutral
      MACD trend
      Positive Bullish
      52-week position
      96% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $60 › 200d $57 — 50d above 200d
      Institutional flow Accumulating
      +1% holders QoQ · +88 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      6.46% of float · ▼ -12.7% MoM · 7.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      564 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $50 Now $69 · 96% Range high $70
      vs 200-day avg +21% vs 50-day avg +15%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Non-GAAP Income from Operations non-GAAP $545M Six Months Ended June 30, 2026 —
      Total cash $2B the end of the first quarter 2026 —
      Non-convertible debt financing $3.7B full year 2025 —
      VOXZOGO commercial markets 55 full year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      BMRN
      Biomarin Pharmaceutical Inc
      this stock
      		$12.97B +16.7% +17.6% 171.8 6.5%
      ONC
      BeOne Medicines Ltd.
      		 $535.83B +21.5% +22179.2% 823.9 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $133.88B +16.5% +46.2% 30.8 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $84.27B +5.0% +20.8% 20.3 3.3%
      ARGX
      Argenx SE
      		 $61.75B +22.8% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      564
      % held
      101.3%
      Net QoQ
      +9.8M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      521
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      12.5M
      Days to cover
      7.4d
      Change
      -1.8M sh
      View
      Short Volume
      Short vol %
      52%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      74
      Value
      $4.5K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      39.8%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Daniel Goldman
      Amount
      $1.0K–$15.0K
      Traded
      Mar 6, 2023
      View
      Financials
      Financials
      Revenue (FY)
      $3.2B
      Net income (FY)
      $348.9M
      EPS diluted
      $1.80
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 18, 2026
      This year
      19
      View
      Proposed Sales
      Value
      $176.7K
      Shares
      3.3K
      Filed
      May 7, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View
      Investor Relations
      Latest news
      BioMarin to Acquire Alesta Therap…
      Published
      Aug 18, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      BMRN -1.3% +18.7% +13.5% +15.5% +16.7%
      SPY -0.4% +2.6% +10.7% +2.7% +12.5%
      vs SPY -0.9% +16.2% +2.7% +12.8% +4.1%
      Key facts CIK 1048477 CUSIP 09061G101 13F (30d) 528 filings 497 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)